TTVI-Logic v1.2
Analysis Presets
Trial Database 3 selected
Primary Outcome: TR Reduction (≤ Moderate)
8.20
1.50–45.10
Pooled RR
0.45–140
95% PI
Prediction Int
77%
τ²=0.95
Heterogeneity
725
3 trials
Population
0.012
Significant
P-value
GRADE Assessment
Efficacy (per 100 patients)
📊 TR Reduction Efficacy
TR Eliminated
TR Persistent
Spontaneous Impr.
🎲 Monte Carlo Success Probability
P(Success)>99%
Sensitivity Parameters
8.8%
Methodology: DerSimonian-Laird Random Effects.
Metric: Risk Ratio (RR) for Success (TR ≤ Moderate).
High Heterogeneity driven by TTVR efficacy.